Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey A Carter

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
International Journal of Cancer|April 6, 2017
Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health systemJie Lin, Abegail Gill, Shelia H Zahm, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 29, 2012
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumorsArun Rajan, Corey A Carter, Ronan J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Future Oncology (London, England)|September 12, 2019
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
International Journal of Cancer|April 6, 2017
Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health systemJie Lin, Abegail Gill, Shelia H Zahm, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 29, 2012
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumorsArun Rajan, Corey A Carter, Ronan J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen eraCorey A Carter, Timothy Donahue, Leon Sun, et al.
Case Reports in Oncology|April 12, 2016
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum DoubletsCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Future Oncology (London, England)|September 12, 2019
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Pageof 6